Shire Rejects AbbVie's $46B Offer In Latest Inversion Try
London-listed drugmaker Shire PLC has rejected another takeover offer from U.S. pharmaceutical company AbbVie Inc. that valued it at about £27.2 billion ($46.3 billion), the companies revealed Friday, in another failed high-profile...To view the full article, register now.
Already a subscriber? Click here to view full article